Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

References

• Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes. 2003;10(1):12–16.
   PubMedGoogle Scholar
• Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–558. doi: 10.1016/S1083-8791(03)00287-8
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86(7):2815–2820. doi: 10.1182/blood.V86.7.2815.2815
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols GW. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103(6):2003–2008. doi: 10.1182/blood-2003-10-3616
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273–282. doi: 10.1086/338624
   PubMed Web of Science ®Google Scholar
• Massoud R, Assi R, Fares E, et al. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. J Clin Virol. 2017;95:36–41. doi: 10.1016/j.jcv.2017.08.006
   PubMed Web of Science ®Google Scholar
• Mai EK, Bertsch U, Dürig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721–1729. doi: 10.1038/leu.2015.80
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Mai EK, Dürig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34(7):1853–1865. doi: 10.1038/s41375-020-0724-1
   PubMed Web of Science ®Google Scholar
• Salwender H, Elmaagacli A, Merz M, et al. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia. 2021;35(10):3007–3011. doi: 10.1038/s41375-021-01298-y
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346. doi: 10.1016/0197-2456(96)00075-X
   PubMedGoogle Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020.
   Google Scholar
• Jacobsen N, Badsberg JH, Lönnqvist B, et al. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant. 1990;5(6):413–418.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402–1412. doi: 10.1182/blood-2010-08-304121
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122(19):3359–3364. doi: 10.1182/blood-2013-05-499830
   PubMed Web of Science ®Google Scholar
• Fowler K, Mucha J, Neumann M, et al. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022;22(1):1659. doi: 10.1186/s12889-022-13971-7
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Ross SR, Dührsen U, et al. Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. Leuk Lymphoma. 2017;58(4):822–833. doi: 10.1080/10428194.2016.1217524
   PubMed Web of Science ®Google Scholar
• Lopez-Sejas N, Campos C, Hassouneh F, et al. Effect of CMV and aging on the differential expression of CD300a, CD161, T-bet, and Eomes on NK cell subsets. Front Immunol. 2016;7:476. doi: 10.3389/fimmu.2016.00476
   PubMed Web of Science ®Google Scholar
• Lutz CT, Moore MB, Bradley S, et al. Reciprocal age related change in natural killer cell receptors for mHC class I. Mech Aging Dev. 2005;126:722–731. doi: 10.1016/j.mad.2005.01.004
   PubMed Web of Science ®Google Scholar
• Hazeldine J, Hampson P, Lord JM. Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity. Aging Cell. 2012;11(5):751–759. doi: 10.1111/j.1474-9726.2012.00839.x
   PubMed Web of Science ®Google Scholar
• Kadambari S, Klenerman P, Pollard AJ. Why the elderly appear to be more severely affected by COVID-19: the potential role of immunosenescence and CMV. Rev Med Virol. 2020;30(5):e2144. doi: 10.1002/rmv.2144
   PubMed Web of Science ®Google Scholar
• Tay KH, Slavin MA, Thursky KA, et al. Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation. Intern Med J. 2022;52(10):1759–1767. doi: 10.1111/imj.15496
   PubMed Web of Science ®Google Scholar